CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
about
Safety of dipeptidyl peptidase 4 inhibitors: a perspective reviewA global comparison of the human and T. brucei degradomes gives insights about possible parasite drug targetsDPP4 deficiency preserved cardiac function in abdominal aortic banding ratsMechanisms of confluence-dependent expression of CD26 in colon cancer cell lines.Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects.Moonlighting adenosine deaminase: a target protein for drug development.Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition.Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters.Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma.Aggressive mature natural killer cell neoplasms: report on a series of 12 European patients with emphasis on flow cytometry based immunophenotype and DNA content of neoplastic natural killer cells.[Dipeptidyl peptidase IV in inflammatory bowel diseases (DPP IV/CD26)].
P2860
Q26863262-42AA70AD-9A93-471D-A0ED-31DD359E1370Q28485518-A4A6C1A9-7092-43AB-9A69-DC90196F1A25Q28538591-240ED899-70CD-4949-B839-C96D4AFDBB8EQ33810055-BFB2B97D-BE4D-49AD-B151-018AED946F9EQ33930280-BE09CCB6-1328-4852-AE84-FAD81E190258Q34507149-FC02D763-4D07-4BB6-8A48-2D47E1CFA5FAQ34566411-9861AE3B-6550-4B23-B1F1-8C73C9441DABQ34681579-A3F88082-5AFC-4AE9-A762-6BD1F7A98563Q36736740-AEF7F6B7-C096-45A3-8B46-EE9C9D399867Q37589156-495AFAA3-DA60-4925-8CCE-9017D67E42CEQ38220597-EC9DB4C1-C334-4FAD-97ED-30A0FDC89529Q39277184-ECF5FFE5-36CD-4218-9732-5DDD8D252F5CQ42776303-5DAC1391-39B8-4B43-AD38-D0B920B673EFQ43151330-6ADAF4E3-782C-4BD2-A0BA-1DFA61A6B74FQ52305766-26109EE7-2A95-4A42-B19F-815C02A878F9Q53060586-DF2A6359-F821-4C8B-AA4D-31B8E66962A1Q53807699-08FAA066-7ACD-403A-A440-D1D47F88CEC4
P2860
CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CD26/dipeptidyl peptidase IV a ...... r cancer and immune disorders.
@ast
CD26/dipeptidyl peptidase IV a ...... r cancer and immune disorders.
@en
type
label
CD26/dipeptidyl peptidase IV a ...... r cancer and immune disorders.
@ast
CD26/dipeptidyl peptidase IV a ...... r cancer and immune disorders.
@en
prefLabel
CD26/dipeptidyl peptidase IV a ...... r cancer and immune disorders.
@ast
CD26/dipeptidyl peptidase IV a ...... r cancer and immune disorders.
@en
P2093
P1476
CD26/dipeptidyl peptidase IV a ...... r cancer and immune disorders.
@en
P2093
Chikao Morimoto
Kei Ohnuma
Masako Abe
Michael A Thompson
Nam H Dang
P304
P356
10.2174/138955707780059853
P577
2007-03-01T00:00:00Z